Navigation Links
Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2012

PALO ALTO, Calif., Jan. 25, 2012 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) today is reporting results for the first quarter of fiscal year 2012 with net earnings of $0.79 per diluted share, down 1 percent from the year-ago quarter. Revenues for the quarter were $625 million, up 8 percent from the year-ago period. Including $48 million in proton therapy backlog, the company ended the first quarter with a $2.5 billion backlog, up 14 percent from the end of the first quarter in fiscal 2011.  

"While we met our guidance for net earnings and revenues, this was a challenging quarter for the company in a variety of ways," said Tim Guertin, president and CEO of Varian Medical Systems.  "We experienced order push outs in our North American oncology business and X-Ray Product orders and sales were hurt by inventory adjustments by our customers in Japan. As anticipated, the gross margin was impacted by a tough year-ago comparison, product mix, and accounting for Scripps proton revenue with zero margin.  Additionally our operating margin was impacted by the dilutive effects of the Calypso acquisition."  

The company ended the first quarter with $606 million in cash and cash equivalents and $188 million of debt.

Oncology SystemsOncology Systems' first quarter revenues totaled $488 million, up 8 percent from the same period of fiscal year 2011.  First-quarter net orders were $485 million, up 6 percent, with a 22 percent increase in international markets offsetting an 11 percent decline in North America versus the comparable year-ago period."Net orders in all international regions were up in solid double digits, comprising nearly 60 percent of the net orders received by this business during the quarter," Guertin said.  "Several orders that we were aiming for in North America during the quarter were pushed out, but we fully expect that we will book them in this fiscal year."

X-Ray ProductsFirst quarter revenues for the X-Ray Products business were $113 million, up 1 percent from the year-ago quarter.  Compared to the corresponding period in fiscal year 2011, X-Ray Products first quarter net orders fell 2 percent to $110 million.

"Our X-Ray Products business experienced weakness related to inventory adjustments among several customers in Japan who appear to have overstocked tubes and panels.  We believe this was related to their efforts to maintain normal production schedules in spite of blackouts following the earthquake and tsunami," said Guertin.  "We expect this region to return to more typical levels as the year progresses."

OtherThe company's Other category, which is comprised of the Security and Inspection Products business, the Varian Particle Therapy business, and the Ginzton Technology Center, recorded first quarter revenues of $25 million, up $9 million from the year-ago period driven principally by revenues from the installation of the Scripps proton system.  Compared to the first quarter of fiscal 2011, net orders in the Other category fell by $10 million to $12 million, principally because of a fall off in the security business versus a comparatively strong year-ago quarter.  

Subsequent to the close of the quarter the company signed a contract and booked an order to supply the King Fahd Medical Center in Saudi Arabia with a $77 million proton therapy system in a new center in Riyadh.Outlook "We remain confident in our growth outlook for fiscal 2012 and expect our businesses to strengthen as the year progresses with annual revenues growing by about 10 percent and earnings per diluted share rising by about 15 percent," said Guertin. "For the second quarter of fiscal 2012, we believe that revenues could increase by about 8 percent over the second quarter of fiscal 2011 total and that net earnings per diluted share could rise by 12 to 13 percent." Investor Conference CallVarian Medical Systems is scheduled to conduct its first quarter fiscal year 2012 conference call at 2 p.m. PT today.  To hear a live webcast or replay of the call, visit the investor relations page on the company's web site at where it will be archived for a year.  To access the call via telephone, dial 1-866-700-0161 from inside the U.S. or 1-617-213-8832 from outside the U.S. and enter confirmation code 37675518.  The replay can be accessed by dialing 1 888 286-8010 from inside the U.S. or 1-617-801-6888 from outside the U.S. and entering confirmation code 39547714.  The telephone replay will be available through 5 p.m. PT, Friday, January 27, 2012.

For automatic "e-mail alerts" regarding Varian news, events, and new investor materials on the website, investors can subscribe on the company website: For additional information, contact investor relations at 1 650 424-5834.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,900 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit

Forward-Looking Statements Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the company's future business, including orders, revenues, backlog, or earnings growth; future financial results; market acceptance of or transition to new products or technology such as the TrueBeam platform and radiographic flat panel detectors, image-guided radiation therapy, stereotactic radiosurgery, filmless X-rays, proton therapy, and security and inspection, and any statements using the terms  "could," "believe," "expects," "appear," "confident," "outlook," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the effect of economic conditions, including the lack of strength of the recovery from the global recession and the effect on capital spending; the impact of the 2010 federal health care legislation and any further health care reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; currency exchange rates and tax rates; demand for the company's products; the company's ability to develop, commercialize, and deploy new products; the company's ability to meet Food and Drug Administration (FDA) and other regulatory requirements for product clearances or to comply with FDA and other regulatory regulations or procedures; changes in the regulatory environment, including with respect to FDA requirements; challenges associated with the successful commercialization of the company's particle therapy business; the effect of adverse publicity; the company's reliance on sole or limited-source suppliers; the impact of reduced or limited demand by purchasers of certain X-ray products, including those located in Japan; the company's ability to maintain or increase margins; the impact of competitive products and pricing; the potential loss of key distributors or key personnel; challenges to public tender awards and the loss of such awards or other orders; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

A summary of earnings and other financial information follows.Varian Medical Systems, Inc. and Subsidiaries Consolidated Statements of Earnings
(Unaudited)(Dollars and shares in millions, except per share amounts)Q1 QTR2012Q1 QTR2011Net orders



592.8  Oncology Systems484.7459.0  X-Ray Products109.8111.9  Security & Inspection Products10.821.3  Varian Particle Therapy 0.60.6  Ginzton Technology Center 0.2-Order backlog






579.9  Oncology Systems487.6452.4  X-Ray Products113.0111.6  Other24.715.9Cost  of  revenues



313.1Gross margin   268.8266.8
As a percent of revenues
43.0%46.0%Operating expenses    Research and development43.838.5  Selling, general and administrative  96.191.3Operating earnings128.9137.0
As a percent of revenues
20.6%23.6%Interest income, net0.30.1Earnings before taxes129.2137.1Taxes on earnings  39.040.6Net earnings  



96.5   As a percent of revenues14.4%16.6%Net earnings per share – basic



0.82Net earnings  per share – diluted



0.80Shares used in the calculation of net earnings per share: Average shares outstanding - basic112.3118.2Average shares outstanding - diluted114.4121.2Varian Medical Systems, Inc. and SubsidiariesCondensed Consolidated Balance Sheets(In thousands)December 30, September 30,2011 2011 (1)(Unaudited)AssetsCurrent assetsCash and cash equivalents




564,457Short-term investment 25,28919,205Accounts receivable, net577,253635,153Inventories444,665409,962Deferred tax assets and other254,153225,840Total current assets1,907,6771,854,617Property, plant and equipment614,995601,115Accumulated depreciation and amortization(334,163)(315,221)Property, plant and equipment, net280,832285,894Goodwill213,017212,452Other assets179,805145,798Total assets$



2,498,761Liabilities and Stockholders' EquityCurrent liabilitiesAccounts payable$



154,946Accrued expenses272,216290,009Deferred revenues142,032140,173Advance payments from customers318,448299,380Product warranty48,48950,128Short-term borrowings175,000181,400Current maturities of long-term debt6,2509,876Total current liabilities1,092,3231,125,912Other long-term liabilities123,405122,708Long-term debt6,2506,250Total liabilities1,221,9781,254,870Stockholders' EquityCommon stock 112,784112,344Capital in excess of par value 530,029500,922Retained earnings and accumulated other comprehensive loss  716,540630,625Total stockholders' equity1,359,3531,243,891Total liabilities and stockholders' equity$



2,498,761(1)  The condensed consolidated balance sheet as of September 30, 2011 was derived from audited financial statements as of that date.FOR INFORMATION CONTACT:
Elisha Finney (650) 424-6803

Spencer Sias (650) 424-5782


SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
(Date:10/9/2015)... REDWOOD CITY, Calif. , Oct. 9, 2015 ... a presentation will be made at the annual European Society ... th to October 14 th , 2015 at the ...  The annual EuSEM is the largest meeting of emergency medicine ... and 90 countries represented. Data from the previously ...
(Date:10/9/2015)... Oct. 9, 2015 Ansun BioPharma announced a ... of America ) regarding the compassionate use of DAS181 ... a respirator who was co-infected with influenza and parainfluenza ... of therapy, O 2 requirement was reduced and ... able to go off the respirator on day 5. ...
(Date:10/9/2015)... , Schweiz, October 9, 2015 Der ... Dr.   Yutaka Kondo und Dr.   Junko Takita ...   2015 " geht an Dr.   Yutaka ... Der " JCA-Mauvernay Award   2015 ... Dr.   Junko Takita    ™ , das ...
Breaking Medicine Technology:
... Nov. 9, 2011 BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX® in the U.S. ... Tom Wegman, will present at the upcoming Lazard Capital ... Wednesday, November 16, 2011 in New York, NY.   ...
... 9, 2011 NeuroDerm , Ltd. ... and pharmacokinetic trial of ND0611, administered as an adjunct ... or Stalevo ® , in patients with advanced Parkinson,s ... sub-cutaneously via a dermal patch to increase the bioavailability ...
Cached Medicine Technology:
(Date:10/10/2015)... York, NY (PRWEB) , ... October 10, 2015 , ... ... some alarming numbers on the growth of cybercrime costs for US companies. The New ... on Tuesday, October 6th. With averages showing increases hovering around 20% among the companies ...
(Date:10/10/2015)... , ... October 10, 2015 , ... Isabel Healthcare will ... , On the heels of the release of the Institute of Medicine’s latest report ... their integration with Cerner solutions that assist healthcare providers and consumers to potentially reduce ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American Osteopathic ... for Graduate Medical Education J. Michael Finley, DO, as the recipient of the ... for his impact on graduate medical education opportunities for osteopathic residents, and his ...
(Date:10/9/2015)... ... 2015 , ... A new health tool that helps identify if a sore ... ) – just in time for the cold and flu season, which the ... many in the U.S., the real start of cold/flu season is the start of ...
(Date:10/9/2015)... ... October 09, 2015 , ... Dentist in Huntington ... orthodontic system that uses clear, plastic aligners. This alternative to braces has become ... which allow patients to complete treatment in privacy. Additionally, Invisalign aligners are removable, ...
Breaking Medicine News(10 mins):
... serious problem that can often be fatal. Methadone has ... addicts. However, the major concern in treating heroin addicts ... is one reason methadone therapy is usually only given ... that an alternative drug therapy combined with psychosocial treatment ...
... researchers are currently testing the safety of hypothermia ... injury. Hypothermia treatment has been shown to be ... but its effectiveness in treating children with traumatic ... decreases inflammation, excitotoxicity (excessive neurotransmitters released with injury ...
... of skin cancer and it has been shown through previous ... sunlight, whose UV rays cause damage to DNA that triggers ... are more prone than others to melanoma. Researchers have now ... people with melanoma that those with fair skin// have lowered ...
... Affective Disorder(SAD) is not all that well understood, but ... sunlight in the winter months. Winter depression involves suffering ... days get longer and nights get shorter. Other SAD ... sleeping for longer than usual. Researchers have now found ...
... hospital in Kolkatta, India recently received a patient, a two-month-old ... suffering from a rare disease caused due to a deficiency ... of 10 million children. Doctors said that the baby was ... On detection the baby, a boy child, was found to ...
... time to its ultraviolet rays, has always been said to be ... shown that even moderate sun exposure can result in moles that ... to sun has been shown as the main risk factor for ... rarest type of skin cancer, is much weaker. It has however, ...
Cached Medicine News:
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
For the quantitative in vitro determination of Aspartate Aminotransferase (AST) in serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: